Metformin Limits the Tumourigenicity of IPS Cells Without Affecting Their Pluripotency

Overview

Journal Sci Rep

Specialty Science

Date 2012 Dec 14

PMID 23236586

Citations 41

Authors

Alejandro Vazquez-Martin

Silvia Cufi

Eugeni Lopez-Bonet

Bruna Corominas-Faja

Cristina Oliveras-Ferraros

Begona Martin-Castillo

Javier A Menendez

Affiliations

Soon will be listed here.

Abstract

The antidiabetic drug metformin efficiently circumvents the dilemma that in reducing the tumourigenicity of stem cells, their essence, specifically their pluripotency, must also be sacrificed. Metformin prevents the occurrence or drastically reduces the size and weight of teratoma-like masses after the transplantation of induced pluripotent stem (iPS) cells into immunodeficient mice. Yet, iPS cells implanted into metformin-treated mice retain full pluripotency, as they produce the same number of distinct tissue types derived from the three embryonic germ layers that is observed in untreated mice. Mechanistically, metformin appears to suppress the Oct4-driven compartment of malignant stem cells responsible for teratocarcinoma growth while safeguarding an intact, Oct4-independent competency to generate terminally differentiated tissues. Metformin's ability to efficiently and specifically control the tumourigenic fate of teratoma-initiating iPS cells without interfering with their pluripotency not only has implications for the clinical use of iPS cells but also in stem cell biology, cancer and ageing.

Citing Articles

Strategies to Improve the Safety of iPSC-Derived β Cells for β Cell Replacement in Diabetes.

Pellegrini S, Zamarian V, Sordi V Transpl Int. 2022; 35:10575.

PMID: 36090777 PMC: 9448870. DOI: 10.3389/ti.2022.10575.

Teratoma Formation Assay for Assessing Pluripotency and Tumorigenicity of Pluripotent Stem Cells.

Miyawaki S, Okada Y, Okano H, Miura K Bio Protoc. 2021; 7(16):e2518.

PMID: 34541178 PMC: 8413610. DOI: 10.21769/BioProtoc.2518.

Metformin: Metabolic Rewiring Faces Tumor Heterogeneity.

Cioce M, Pulito C, Strano S, Blandino G, Fazio V Cells. 2020; 9(11).

PMID: 33182253 PMC: 7695274. DOI: 10.3390/cells9112439.

A technique for removing tumourigenic pluripotent stem cells using rBC2LCN lectin.

Haramoto Y, Onuma Y, Mawaribuchi S, Nakajima Y, Aiki Y, Higuchi K Regen Ther. 2020; 14:306-314.

PMID: 32462059 PMC: 7240284. DOI: 10.1016/j.reth.2020.03.017.

Role of CD133 in human embryonic stem cell proliferation and teratoma formation.

Wang H, Gong P, Li J, Fu Y, Zhou Z, Liu L Stem Cell Res Ther. 2020; 11(1):208.

PMID: 32460847 PMC: 7251672. DOI: 10.1186/s13287-020-01729-0.

References

Vazquez-Martin A, Oliveras-Ferraros C, Cufi S, Martin-Castillo B, Menendez J . Metformin and energy metabolism in breast cancer: from insulin physiology to tumour-initiating stem cells. Curr Mol Med. 2010; 10(7):674-91. DOI: 10.2174/156652410792630625. View

Vazquez-Martin A, Oliveras-Ferraros C, Del Barco S, Martin-Castillo B, Menendez J . The antidiabetic drug metformin: a pharmaceutical AMPK activator to overcome breast cancer resistance to HER2 inhibitors while decreasing risk of cardiomyopathy. Ann Oncol. 2009; 20(3):592-5. DOI: 10.1093/annonc/mdn758. View

Anisimov V . Metformin for aging and cancer prevention. Aging (Albany NY). 2010; 2(11):760-74. PMC: 3006019. DOI: 10.18632/aging.100230. View

Brickman J, Burdon T . Pluripotency and tumorigenicity. Nat Genet. 2002; 32(4):557-8. DOI: 10.1038/ng1202-557. View

Vazquez-Martin A, Oliveras-Ferraros C, Del Barco S, Martin-Castillo B, Menendez J . The anti-diabetic drug metformin suppresses self-renewal and proliferation of trastuzumab-resistant tumor-initiating breast cancer stem cells. Breast Cancer Res Treat. 2010; 126(2):355-64. DOI: 10.1007/s10549-010-0924-x. View

Lengner C, Welstead G, Jaenisch R . The pluripotency regulator Oct4: a role in somatic stem cells?. Cell Cycle. 2008; 7(6):725-8. DOI: 10.4161/cc.7.6.5573. View

Vander Heiden M, Cantley L, Thompson C . Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009; 324(5930):1029-33. PMC: 2849637. DOI: 10.1126/science.1160809. View

Grahame Hardie D . AMP-activated protein kinase: an energy sensor that regulates all aspects of cell function. Genes Dev. 2011; 25(18):1895-908. PMC: 3185962. DOI: 10.1101/gad.17420111. View

Song C, Lee H, Dings R, Williams B, Powers J, Dos Santos T . Metformin kills and radiosensitizes cancer cells and preferentially kills cancer stem cells. Sci Rep. 2012; 2:362. PMC: 3324825. DOI: 10.1038/srep00362. View

10.

Wang J, Alexander P, Wu L, Hammer R, Cleaver O, McKnight S . Dependence of mouse embryonic stem cells on threonine catabolism. Science. 2009; 325(5939):435-9. PMC: 4373593. DOI: 10.1126/science.1173288. View

11.

Del Barco S, Vazquez-Martin A, Cufi S, Oliveras-Ferraros C, Bosch-Barrera J, Joven J . Metformin: multi-faceted protection against cancer. Oncotarget. 2011; 2(12):896-917. PMC: 3282095. DOI: 10.18632/oncotarget.387. View

12.

Liu G, Suzuki K, Qu J, Sancho-Martinez I, Yi F, Li M . Targeted gene correction of laminopathy-associated LMNA mutations in patient-specific iPSCs. Cell Stem Cell. 2011; 8(6):688-94. PMC: 3480729. DOI: 10.1016/j.stem.2011.04.019. View

13.

Menendez J, Cufi S, Oliveras-Ferraros C, Vellon L, Joven J, Vazquez-Martin A . Gerosuppressant metformin: less is more. Aging (Albany NY). 2011; 3(4):348-62. PMC: 3117449. DOI: 10.18632/aging.100316. View

14.

Prigione A, Lichtner B, Kuhl H, Struys E, Wamelink M, Lehrach H . Human induced pluripotent stem cells harbor homoplasmic and heteroplasmic mitochondrial DNA mutations while maintaining human embryonic stem cell-like metabolic reprogramming. Stem Cells. 2011; 29(9):1338-48. DOI: 10.1002/stem.683. View

15.

Martin-Castillo B, Vazquez-Martin A, Oliveras-Ferraros C, Menendez J . Metformin and cancer: doses, mechanisms and the dandelion and hormetic phenomena. Cell Cycle. 2010; 9(6):1057-64. DOI: 10.4161/cc.9.6.10994. View

16.

Corominas-Faja B, Quirantes-Pine R, Oliveras-Ferraros C, Vazquez-Martin A, Cufi S, Martin-Castillo B . Metabolomic fingerprint reveals that metformin impairs one-carbon metabolism in a manner similar to the antifolate class of chemotherapy drugs. Aging (Albany NY). 2012; 4(7):480-98. PMC: 3433934. DOI: 10.18632/aging.100472. View

17.

Knoepfler P . Deconstructing stem cell tumorigenicity: a roadmap to safe regenerative medicine. Stem Cells. 2009; 27(5):1050-6. PMC: 2733374. DOI: 10.1002/stem.37. View

18.

Raya A, Rodriguez-Piza I, Guenechea G, Vassena R, Navarro S, Barrero M . Disease-corrected haematopoietic progenitors from Fanconi anaemia induced pluripotent stem cells. Nature. 2009; 460(7251):53-9. PMC: 2720823. DOI: 10.1038/nature08129. View

19.

Blum B, Bar-Nur O, Golan-Lev T, Benvenisty N . The anti-apoptotic gene survivin contributes to teratoma formation by human embryonic stem cells. Nat Biotechnol. 2009; 27(3):281-7. DOI: 10.1038/nbt.1527. View

20.

Menendez S, Camus S, Herreria A, Paramonov I, Morera L, Collado M . Increased dosage of tumor suppressors limits the tumorigenicity of iPS cells without affecting their pluripotency. Aging Cell. 2011; 11(1):41-50. DOI: 10.1111/j.1474-9726.2011.00754.x. View